



## OUR COMPOUNDS

Our extensive oncology clinical trial programme has produced two approved drugs, as well as several other investigational compounds which are currently being investigated across a broad range of tumour types. Find out more below.

COMPOUND	TARGET	FOCUS AREA	DEVELOPMENT STAGE			
			PHASE I	PHASE II	PHASE III	APPROVED
<b>Afatinib*</b> NCE po (GIOTRIF <sup>®</sup> )	<b>EGFR</b> (ErbB1); <b>HER2</b> (ErbB2); <b>ErbB3</b> ; <b>ErbB4</b>	Non-small cell lung cancer first line epidermal growth factor receptor mutation-positive Squamous histology non-small cell lung cancer	1	2	3	A
		Head and neck squamous cell carcinoma	1	2	3	A
		Urothelial carcinoma	1	2	3	A
<b>Nintedanib**</b> NCE po (VARGATEF <sup>®</sup> )	<b>VEGFR</b> ; <b>FGFR</b> ; <b>PDGFR</b>	Non-small cell lung cancer second line	1	2	3	A
		Malignant pleural mesothelioma	1	2	3	A
<b>BI 695502<sup>†</sup></b> Bevacizumab biosimilar candidate	<b>VEGF</b>	Non-squamous non-small cell lung cancer Metastatic colorectal cancer	1	2	3	A
<b>Xentuzumab<sup>‡</sup></b> NBE iv	<b>IGF ligand</b>	Breast cancer (Ph I/II) Castration-resistant prostate cancer (Ph I/II)	1	2	3	A
		Solid tumours Non-small cell lung cancer	1	2	3	A
<b>BI 836858<sup>‡</sup></b> NBE iv	<b>CD33</b>	Acute myeloid leukaemia Myelodysplastic syndrome	1	2	3	A
<b>BI 836826<sup>‡</sup></b> NBE iv	<b>CD37</b>	Chronic lymphocytic leukaemia Diffuse large B-cell lymphoma (Ph I/II)	1	2	3	A
		Chronic lymphocytic leukaemia Non-Hodgkin lymphoma	1	2	3	A
<b>BI 836880<sup>‡</sup></b> NBE iv	<b>VEGF/Ang-2</b>	Solid tumours	1	2	3	A
<b>BI 1361849<sup>‡</sup></b> mRNA-based ICV (CV9202)	<b>NY-ESO-1</b> ; <b>MAGE C1</b> ; <b>MAGE C2</b> ; <b>TPBG</b> ; <b>Survivin</b> ; <b>MUC1</b>	Non-small cell lung cancer	1	2	3	A
<b>BI 754091<sup>‡</sup></b> NBE iv	<b>PD-1</b>	Solid tumours	1	2	3	A
<b>BI 894999<sup>‡</sup></b> NCE po	<b>BET</b>	Solid tumours - non-Hodgkin lymphoma	1	2	3	A
<b>BI 754091/ BI 754111<sup>‡</sup></b> NBE iv	<b>PD-1/LAG3</b>	Solid tumours	1	2	3	A
<b>BI 754091/ BI 891065<sup>‡</sup></b> NCE po	<b>PD-1/SMAC</b>	Solid tumours	IN PREPARATION			

\*Afatinib is approved in more than 65 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF<sup>®</sup>, in the US under the brand name GILOTRIF<sup>®</sup> and in India under the brand name Xovoltib<sup>®</sup>; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

<sup>†</sup>Nintedanib is approved in the EU under the brand name VARGATEF<sup>®</sup> for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

<sup>‡</sup>This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

Ang-2, angiopoietin-2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; iv, intravenous; LAG3, lymphocyte activation gene 3 protein; MAGE, melanoma-associated antigen; mRNA-based ICV, messenger ribonucleic acid-based immunotherapeutic cancer vaccine; MUC1, mucin 1, cell surface associated; NBE, new biological entity; NCE, new chemical entity; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PD-1, programmed cell death protein 1; po, orally; PDGFR, platelet-derived growth factor receptor; SMAC, second mitochondria-derived activator of caspase; TKI, tyrosine kinase inhibitor; TPBG, trophoblast glycoprotein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.